Department of Thoracic Surgery, Hospital Universitari de Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), Feixa Llarga s/n., 08907, L´Hospitalet de Llobregat, Barcelona, Spain.
Unit of Human Anatomy, Department of Pathology and Experimental Therapeutics, Medical School, University of Barcelona, Barcelona, Spain.
BMC Pulm Med. 2021 Mar 2;21(1):75. doi: 10.1186/s12890-021-01446-1.
The aim of this study was to assess the effect of the lymphocyte-to-monocyte ratio (LMR), neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio on overall survival and disease-free survival in patients with lung cancer treated with radical surgery.
We performed a retrospective review of patients with lung cancer who prospectively underwent radical resection between 2004 and 2012. Blood samples were taken as part of the preoperative workup. The inflammatory markers studied were absolute values of lymphocytes, monocytes, neutrophils and platelets, with subsequent calculation of ratios. Median follow-up was 52 months.
Two hundred and sixty-eight patients underwent surgery, of whom 218 (81.3%) were men. Mean age was 62.9 ± 8.7 years. A lymphocyte-to-monocyte ratio ≥ 2.5 was independently associated with longer disease-free survival (hazard ratio [HR] 0.476 (0.307-0.738), p = 0.001) and longer overall survival (HR, 0.546; 95% CI: 0.352-0.846; p = 0.007), in models adjusted for age, sex, stage, and type of resection. No other systemic inflammatory marker showed a significant association.
Preoperative LMR is an independent prognostic factor of overall survival and recurrence-free survival in patients with surgically-resected early stage lung cancer.
本研究旨在评估淋巴细胞与单核细胞比值（LMR）、中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值对接受根治性手术治疗的肺癌患者总生存和无病生存的影响。
我们对 2004 年至 2012 年间前瞻性接受根治性切除术的肺癌患者进行了回顾性分析。血液样本是术前检查的一部分。所研究的炎症标志物为淋巴细胞、单核细胞、中性粒细胞和血小板的绝对值，随后计算比值。中位随访时间为 52 个月。
268 例患者接受了手术，其中 218 例（81.3%）为男性。平均年龄为 62.9±8.7 岁。淋巴细胞与单核细胞比值≥2.5 与无病生存时间延长独立相关（风险比 [HR]0.476[0.307-0.738]，p=0.001）和总生存时间延长（HR0.546；95%CI：0.352-0.846；p=0.007），在调整年龄、性别、分期和切除类型的模型中。其他系统性炎症标志物均无显著相关性。
术前 LMR 是手术切除早期肺癌患者总生存和无复发生存的独立预后因素。
